Dechra Pharmaceuticals PLC
DCHPF · OTC
6/30/2023 | 12/31/2022 | 6/30/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 1.8% | 8% | 5.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 55% | 57.9% | 56.1% | 56.8% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | $0 | $0 | $0 |
| % Margin | -7.8% | 12.4% | 11% | 17.3% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | $0 | $0 | $0 |
| Tax Expense | -$0 | $0 | $0 | $0 |
| Net Income | -$0 | $0 | $0 | $0 |
| % Margin | -13.1% | 6% | 5% | 12.2% |
| EPS | -0.44 | 0.199 | 0.16 | 0.38 |
| % Growth | -321.6% | 23.8% | -57.8% | – |
| EPS Diluted | -0.44 | 0.199 | 0.16 | 0.38 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | $0 | $0 | $0 |
| % Margin | -4.1% | 12.5% | 17.5% | 19.5% |